We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

165 hedge funds and large institutions have $190M invested in Akebia Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 48 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 48

26% more call options, than puts

Call options by funds: $976K | Put options by funds: $773K

2.1% less ownership

Funds ownership: 46.64% → 44.54% (-2.1%)

7% less funds holding

Funds holding: 177 → 165 (-12)

30% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 33

44% less capital invested

Capital invested by funds: $338M → $190M (-$147M)

Holders
165
Holders Change
-12
Holders Change %
-6.78%
% of All Funds
2.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
63
Reduced
48
Closed
33
Calls
$976K
Puts
$773K
Net Calls
+$203K
Net Calls Change
-$699K

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$6.15M
2
State Street
State Street
Massachusetts
+$3.86M
3
HF
HRT Financial
New York
+$3.34M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.1M
5
First Trust Advisors
First Trust Advisors
Illinois
+$1.97M

Top Sellers

1
MB
MPM BioImpact
Massachusetts
-$7.89M
2
AAA
Affinity Asset Advisors
New York
-$6.69M
3
Morgan Stanley
Morgan Stanley
New York
-$6.46M
4
UBS Group
UBS Group
Switzerland
-$5.81M
5
Franklin Resources
Franklin Resources
California
-$5.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$31.1M +$1.09M +521,394 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$25.8M +$982K +468,940 +3%
State Street
3
State Street
Massachusetts
$22M +$3.86M +1,842,792 +16%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$10.1M +$193K +92,226 +1%
Goldman Sachs
5
Goldman Sachs
New York
$7.58M +$6.15M +2,938,624 +166%
Citadel Advisors
6
Citadel Advisors
Florida
$7.51M +$3.1M +1,479,711 +46%
Renaissance Technologies
7
Renaissance Technologies
New York
$5.78M -$753K -359,594 -9%
Qube Research & Technologies (QRT)
8
Qube Research & Technologies (QRT)
United Kingdom
$4.82M -$451K -215,417 -7%
Citigroup
9
Citigroup
New York
$3.92M +$1.09M +519,511 +27%
Northern Trust
10
Northern Trust
Illinois
$3.72M -$363K -173,302 -7%
Bank of America
11
Bank of America
North Carolina
$3.63M +$982K +468,911 +26%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$3.54M +$108K +51,796 +2%
Charles Schwab
13
Charles Schwab
California
$3.51M +$22.1K +10,539 +0.5%
NCM
14
Nantahala Capital Management
Connecticut
$3.22M – – –
Millennium Management
15
Millennium Management
New York
$2.66M -$2.52M -1,203,768 -42%
HF
16
HRT Financial
New York
$2.61M +$3.34M +1,594,539 +6,430%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$2.53M -$410K -195,679 -11%
Federated Hermes
18
Federated Hermes
Pennsylvania
$2.08M +$1.36M +651,800 +102%
Morgan Stanley
19
Morgan Stanley
New York
$1.98M -$6.46M -3,086,385 -72%
Squarepoint
20
Squarepoint
New York
$1.97M +$931K +444,498 +57%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$1.81M +$448K +213,817 +23%
First Trust Advisors
22
First Trust Advisors
Illinois
$1.52M +$1.97M +941,657 New
Barclays
23
Barclays
United Kingdom
$1.49M -$538K -256,726 -22%
UBS Group
24
UBS Group
Switzerland
$1.4M -$5.81M -2,774,699 -76%
Wellington Management Group
25
Wellington Management Group
Massachusetts
$1.27M -$174K -83,339 -10%
1
2 3 4 5

AKBA Hedge Fund Activity: Q4 2025 in Review

165 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2025, worth a combined $190M — down 44% from $338M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of AKBA and 23 opened new positions — a net loss of 10 holders — while 48 trimmed existing stakes and 63 added.

The largest buyer was Goldman Sachs, adding an estimated $6.15M. The largest seller was MPM BioImpact, exiting entirely with an estimated $7.89M sold.

  • 165 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2025, down from 177 in Q3 2025.
  • Funds reported $190M of Akebia Therapeutics stock for Q4 2025, down 44% quarter-over-quarter.
  • 23 funds opened new Akebia Therapeutics positions in Q4 2025 and 33 closed out, a net change of -10 holders.
  • The largest Akebia Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $6.15M added.
  • The largest Akebia Therapeutics seller in Q4 2025 was MPM BioImpact, an estimated $7.89M sold.

Based on aggregated 13F filings for Q4 2025.